NCT05138250View on ClinicalTrials.gov

A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

July 31, 2025

Conditions
COPD
Interventions
DRUG

Mepolizumab 100 MG

participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks

Trial Locations (1)

S5 7AU

Clinical Research Facility - NGH, Sheffield

All Listed Sponsors
collaborator

University of Sheffield

OTHER

lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER